Form 4: CG Oncology Director, Susan E. Graf, Acquires Stock Options

Director Susan E. Graf acquired stock options for 15,600 shares of CG Oncology common stock on October 4, 2024.

Summary

• Susan E. Graf, a director of CG Oncology, Inc., filed a Form 4 to report changes in beneficial ownership.
• On October 4, 2024, Graf acquired stock options for 15,600 shares of CG Oncology common stock at an exercise price of $36.63.
• The options vest monthly over a year, starting October 4, 2024, contingent upon continuous service to the Issuer.
• The options expire on October 3, 2034.
• Following the transaction, Graf directly owns 15,600 derivative securities.

Sentiment

Score: 6

Explanation: Neutral sentiment as it's a standard disclosure of stock option grants to a director. It doesn't inherently indicate positive or negative performance.

Positives

• The acquisition of stock options by a director may signal confidence in the company's future performance.

Industry Context

Form 4 filings are routine disclosures required by the SEC to provide transparency regarding insider transactions in publicly traded companies. This filing indicates a director's acquisition of stock options, which is a common form of executive compensation.

Stakeholder Impact

• The stock option grant aligns the director's interests with those of the shareholders, potentially incentivizing actions that increase shareholder value.

Key Dates